Literature DB >> 32064950

Hydroxypropyl beta cyclodextrin: a water-replacement agent or a surfactant upon spray freeze-drying of IgG with enhanced stability and aerosolization.

Shahriar Milani1, Homa Faghihi2, Abdolhosein Roulholamini Najafabadi1, Mohsen Amini3, Hamed Montazeri2, Alireza Vatanara1.   

Abstract

The great potential of hydroxypropyl beta-cyclodextrin (HPßCD), as a dried-protein stabilizer, has been attributed to various mechanisms namely water-replacement, vitrification and surfactant-like effects. Highlighting the best result in our previous study (weight ratio IgG: HPßCD of 1:0.4), herein we designed to evaluate the efficacy of upper (1:2) and lower (1:0.05) ratios of HPßCD in stabilization and aerosol properties of spray freeze-dried IgG. The protective effect of HPβCD, as measured by size exclusion chromatography (SEC-HPLC) was most pronounced at C3' and C3″, IgG:trehalose:HPβCD ratios of 1:2:0.25 and 1:2:0.05 with aggregation rate constants of 0.46 ± 0.02 and 0.58 ± 0.01 (1/month), respectively. The secondary conformations were analyzed through Fourier transform infrared spectroscopy (FTIR) and all powders well-preserved with the lack of any visible fragments qualified through sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PPAGE). Scanning electron microscopy (SEM) and twin stage impinger (TSI) were employed to characterize the suitability of particles for further inhalation therapy of antibodies and the highest values of fine particle fraction (FPF) were achieved by C3' and C3″, 56.43 and 48.12%. The powders produced at the current ratio 1:2:0.25 and 1:2:0.05 are superior to our previous examination with regards to manifesting lower aggregation and comparable FPF values.

Entities:  

Keywords:  HPβCD; IgG; Spray freeze-drying; aerosolization; direct binding; surface activity

Year:  2020        PMID: 32064950     DOI: 10.1080/03639045.2020.1724131

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  8 in total

1.  Spray-Dried and Spray-Freeze-Dried Powder Formulations of an Anti-Interleukin-4Rα Antibody for Pulmonary Delivery.

Authors:  Harry W Pan; Han Cong Seow; Jason C K Lo; Jinlin Guo; Lingqiao Zhu; Susan W S Leung; Chenghai Zhang; Jenny K W Lam
Journal:  Pharm Res       Date:  2022-07-25       Impact factor: 4.580

2.  Investigating the stabilisation of IFN-α2a by replica exchange molecular dynamics simulation.

Authors:  Daixi Li; Peiqin Chen; Qingli Dong; Baolin Liu; Wujie Zhang; Dong-Qing Wei; Baisong Guo
Journal:  J Mol Model       Date:  2022-07-26       Impact factor: 2.172

3.  Design and Characterization of Spray-Dried Proliposomes for the Pulmonary Delivery of Curcumin.

Authors:  Islam M Adel; Mohamed F ElMeligy; Mohamed E A Abdelrahim; Amr Maged; AbdelFattah A Abdelkhalek; Azza M M Abdelmoteleb; Nermeen A Elkasabgy
Journal:  Int J Nanomedicine       Date:  2021-04-07

Review 4.  Pharmaceutical protein solids: Drying technology, solid-state characterization and stability.

Authors:  Yuan Chen; Tarun Tejasvi Mutukuri; Nathan E Wilson; Qi Tony Zhou
Journal:  Adv Drug Deliv Rev       Date:  2021-03-08       Impact factor: 15.470

5.  Inhalable Protein Powder Prepared by Spray-Freeze-Drying Using Hydroxypropyl-β-Cyclodextrin as Excipient.

Authors:  Jason C K Lo; Harry W Pan; Jenny K W Lam
Journal:  Pharmaceutics       Date:  2021-04-24       Impact factor: 6.321

6.  Next-Generation COVID-19 Vaccines Should Take Efficiency of Distribution into Consideration.

Authors:  Khaled AboulFotouh; Zhengrong Cui; Robert O Williams
Journal:  AAPS PharmSciTech       Date:  2021-04-09       Impact factor: 3.246

7.  Advancements in Particle Engineering for Inhalation Delivery of Small Molecules and Biotherapeutics.

Authors:  Rachel Yoon Kyung Chang; Hak-Kim Chan
Journal:  Pharm Res       Date:  2022-09-07       Impact factor: 4.580

8.  Safety of inhaled ivermectin as a repurposed direct drug for treatment of COVID-19: A preclinical tolerance study.

Authors:  Suzan M Mansour; Rehab N Shamma; Kawkab A Ahmed; Nirmeen A Sabry; Gamal Esmat; Azza A Mahmoud; Amr Maged
Journal:  Int Immunopharmacol       Date:  2021-07-23       Impact factor: 4.932

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.